From: Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle
Radiolabeling experiments | 1 | 2 | 3 | 4 |
---|---|---|---|---|
% Efficiency | 91 | 94 | 94 | 98 |
% Radiochemical purity | 98 | 100 | 100 | 100 |
% Immunoreactivity on | ||||
 PSMA positive cells | ||||
  PC3-PIP | 91 | 82 | 82 | 88 |
  LNCaP | 84 | 82 | 75 | 80 |
 PSMA negative cells | ||||
  PC3 | 1.3 | 1.1 | 2.0 | 3.2 |
  A431 | 0.9 | 0.2 | 0.4 | 0.4 |
Specific Activity (MBq/mg) | 166.5 | 196.1 | 381.1 | 432.9 |